Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study
Authors' conclusion
This study demonstrated for the first time that long-term treatment with denosumab is effective and safe in patients with osteoporosis due to secreting pituitary adenoma.
Study context
- Population
- Patients with osteoporosis due to secreting pituitary adenoma: hyperprolactinemia due to PRL-secreting PAs (5, 29.4%), acromegaly (6, 35.3%), CD (6, 35.3%); prevalent FF in 4 (23.5%)
- Participants
- 17 patients
- Outcome
- Frequency of fragility fractures and % BMD changes
- Follow-up
- 1, 2, 5 and 10 years of treatment
Methodological detailsexploratory
- Exploratory
Main finding
As reported in the abstract
1, 2, 5 and 10 years
- Incident FF: single patient with acromegaly, at 2 and at 5 years
- 1 patient
- Femoral neck bone mineral density (BMD) increased, 1 year
- 11 patients (64.7%)
- Femoral neck BMD increased, 2 years
- 9 patients (52.9%)
- Femoral neck BMD increased, 5 years
- 8 patients (47.1%)
- Femoral neck BMD increased, 10 years
- 2 patients (66.7%)
- Lumbar spine BMD improved, 1 year
- all patients (100%)
- Lumbar spine BMD improved, 2 years
- 16 patients (100%)
- Lumbar spine BMD improved, 5 years
- 11 patients (100%)
- Lumbar spine BMD improved, 10 years
- 2 patients (66.7%)
Observational data: associations, not effects.
Safety
- Drug-related adverse events
- 0
Original publication
Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study. Pituitary. Published 19 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →